PROCEPT BioRobotics Appoints Mary Garrett to Board of Directors
04 1월 2022 - 9:00PM
PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical
robotics company focused on advancing patient care by developing
transformative solutions in urology, today announced the
appointment of Mary Garrett to its Board of Directors.
Ms. Garrett most recently served on the board of Hillrom
Corporation which was acquired by Baxter International Inc. in
December 2021. Ms. Garrett was the governance committee chair and
served on the audit committee of Hill-Rom. She also previously
served as a board member and was on the audit committee of Ethan
Allen Interiors, Inc. Prior to these roles and her retirement in
2015, Ms. Garrett was the Chief Marketing Officer, Global Markets
for IBM Corporation.
“Ms. Garrett’s impressive understanding of the technology
industry and expertise in organizational development make her
ideally suited to join PROCEPT’s board,” said Reza Zadno, PROCEPT
CEO. “Her prior experience serving in multiple roles on public
company boards and as a global marketing leader in large and
developing markets will be very beneficial to our growing
company.”
"I am pleased to join PROCEPT’s Board of Directors and be a part
of a company that is using technology to advance patient care. The
company’s rapid growth and ability to capture a large and expanding
market are exciting, and I am looking forward to helping PROCEPT
achieve these goals,” said Ms. Garrett.
With the appointment of Ms. Garrett, the Board of Directors of
PROCEPT BioRobotics Corporation increased the number of directors
on the Board to nine members.
About PROCEPT BioRobotics CorporationPROCEPT is
a surgical robotics company focused on advancing patient care by
developing transformative solutions in urology. PROCEPT develops,
manufactures and sells the AquaBeam Robotic System, an advanced,
image-guided, surgical robotic system for use in minimally-invasive
urologic surgery with an initial focus on treating benign prostatic
hyperplasia, or BPH. BPH is the most common prostate disease and
impacts approximately 40 million men in the United States. PROCEPT
designed Aquablation therapy to deliver effective, safe and durable
outcomes for males suffering from lower urinary tract symptoms, or
LUTS, due to BPH that are independent of prostate size and shape or
surgeon experience. PROCEPT has developed a significant and growing
body of clinical evidence, which includes nine clinical studies and
over 100 peer-reviewed publications, supporting the benefits and
clinical advantages of Aquablation therapy.
Investor Contact:Gilmartin GroupMatt Bacso,
CFAMatt.bacso@gilmartinir.com
PROCEPT BioRobotics (NASDAQ:PRCT)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
PROCEPT BioRobotics (NASDAQ:PRCT)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024